Clinical Research Directory
Browse clinical research sites, groups, and studies.
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Sponsor: Atom Therapeutics Co., Ltd
Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Official title: Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-01-26
Completion Date
2026-08-31
Last Updated
2026-01-26
Healthy Volunteers
No
Interventions
ABP-671 plus allopurinol
All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol； Period 2 (Day 1-7): Allopurinol Plus ABP-671； Period 3 (Day 1-7): ABP-671；
Locations (1)
Wakefield Clinical Research
Cary, North Carolina, United States